3-氧代哌啶-4-甲酸乙酯盐酸盐 | 72738-09-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 3-氧代哌啶-4-甲酸乙酯盐酸盐
• 中文别名: 4-哌啶羧基LICACID,3-氧代-,乙基酯
• 英文名称: ethyl 3-oxopiperidine-4-carboxylate hydrochloride
• 英文别名: Ethyl 3-oxopiperidin-1-ium-4-carboxylate;chloride；ethyl 3-oxopiperidin-1-ium-4-carboxylate;chloride
• CAS: 72738-09-1
• 化学式: C₈H₁₃NO₃*ClH
• 分子量: 207.657
• InChiKey: VMVUBCKFICINHZ-UHFFFAOYSA-N

物化性质

• 熔点：
  200-202℃ (methanol ethyl acetate )

计算性质

• 辛醇/水分配系数(LogP)：
  0.15
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  55.4
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl 3-oxopiperidine-4-carboxylate, HCl
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 3-oxopiperidine-4-carboxylate, HCl
CAS number: 72738-09-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H13NO3.ClH
Molecular weight: 207.7

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氧代哌啶-4-甲酸乙酯盐酸盐 在 盐酸 、 sodium hypobromide 、 氨 、 碳酸氢钠 、 potassium carbonate 、 三乙胺 、 sodium hydroxide 作用下， 以 乙醇 、 二氯甲烷 、 水 、 丙酮 、 乙腈 为溶剂， 反应 25.0h， 生成 (3E)-3-methoxyimino-4-methylpiperidin-4-amine
  参考文献：
  名称：

  7-（3-烷氧基亚氨基-4-氨基-4-甲基哌啶-1-基）氟喹诺酮衍生物的合成及体外抗菌活性

  摘要：

  设计，合成和评价了一系列新颖的7-（3-烷氧基亚氨基-4-氨基-4-甲基哌啶-1-基）氟喹诺酮衍生物，并对其体外抗菌活性和细胞毒性进行了评估。所有目标化合物均对测试的革兰氏阳性和革兰氏阴性菌株具有有效的抗菌活性，并在抑制包括MRSA的金黄色葡萄球菌，包括MRSE的表皮葡萄球菌和肺炎链球菌的生长方面表现出良好的效力（MIC：0.125–4μg/毫升）。化合物22对革兰氏阳性菌株的活性最高，对吉肠沙星，加替沙星和左氧氟沙星对粪肠球菌的效力比其高4-16倍分别比左氧氟沙星对表皮葡萄球菌09-6和肺炎链球菌08-4的效力高16倍和4倍。

  DOI：

  10.1016/j.ejmech.2011.03.026
• 作为产物：
  描述：

  1-苄基-3-氧杂-4-哌啶甲酸乙酯 在 palladium on activated charcoal 盐酸 、 氢气 作用下， 以 乙醇 、 水 为溶剂， 反应 48.0h， 以87%的产率得到3-氧代哌啶-4-甲酸乙酯盐酸盐
  参考文献：
  名称：

  A Study of Baker's Yeast Reduction of Piperidone-carboxylates.

  摘要：

  The stereoselective baker's yeast reduction of various N-protected piperidone-carboxylic acids have been studied, and the enantioselectivity was found to be widely dependent on whether fermenting or non-fermenting conditions were employed. Thus reaction of N-tert-butoxycarbonyl-4-oxopiperidine-3-carboxylic acid ethyl ester (6) with fermenting baker's yeast gave almost racemic N-tert-butoxycarbonyl-4-hydroxypiperidine-3-carboxylic acid ethyl ester (7), however, with complete diastereoselectivity. Reduction of 6 with non-fermenting yeast gave 7 with a 24-41% enantiomeric excess. Similarly, reduction of N-tert-butoxycarbonyl-3-oxopiperidine-4-carboxylic acid ethyl ester (17) with fermenting baker's yeast gave racemic N-tert-butoxycarbonyl-3-hydroxypiperidine-4-carboxylic acid ethyl ester [(+/-)-18] diastereoselectively. A convenient method for determining the enantiomeric excess of the hydroxypiperidine carboxylic acids derivatives was found in the reaction with Sanger's reagent followed by HPLC on a chiral column.

  DOI：

  10.3891/acta.chem.scand.52-0461

文献信息

• Identification and Optimization of Pyrrolidine Derivatives as Highly Potent Ghrelin Receptor Full Agonists
  作者：Martin Cooper、Antonio Llinas、Peter Hansen、Moya Caffrey、Asim Ray、Stina Sjödin、Igor Shamovsky、Hiroki Wada、Tina Jellesmark Jensen、Ulf Sivars、Leif Hultin、Ulf Andersson、Sara Lundqvist、Karin Gedda、Lisa Jinton、Nina Krutrök、Richard Lewis、Paul Jansson、Cristina Gardelli

  DOI：10.1021/acs.jmedchem.0c00828

  日期：2020.9.10

  adipogenesis and therefore has been considered a promising therapeutic target for catabolic conditions. We previously reported on the synthesis and properties of an indane based series of ghrelin receptor full agonists which led to a sustained increase of insulin-like growth factor-1 in a dog pharmacodynamic study. Herein we report on the identification of a series of pyrrolidine or piperidine based

  肌肉萎缩和恶病质是罹患癌症，慢性阻塞性肺疾病和其他几种慢性疾病的患者中的常见合并症。肽激素生长激素释放肽发挥多效性作用，包括刺激生长激素分泌和随后增加胰岛素样生长因子-1水平，这是肌肉生长和修复的重要介质。Ghrelin还作用于炎症，食欲和脂肪形成，因此被认为是分解代谢疾病的有希望的治疗靶标。我们先前曾报道过基于茚满的系列生长素释放肽受体完全激动剂的合成和性质，该合成和性质在狗药效学研究中导致胰岛素样生长因子-1的持续增加。
• [EN] ROR NUCLEAR RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS NUCLÉAIRES ROR
  申请人：ABBVIE INC

  公开号：WO2016198908A1

  公开（公告）日：2016-12-15

  The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.

  本发明提供了式(I)化合物的药物可接受的盐、前药、生物活性代谢物、立体异构体和它们的同分异构体，其中变量如本文所述定义。本发明的化合物用于治疗免疫性疾病。
• Discovery of a novel class anti-proliferative agents and potential inhibitors of EGFR tyrosine kinases based on 4-anilinotetrahydropyrido[4,3-d]pyrimidine scaffold: Design, synthesis and biological evaluations
  作者：Yong Zhang、Kai Zhang、Meng Zhao、Lixia Zhang、Mingze Qin、Shuchun Guo、Yanfang Zhao、Ping Gong

  DOI：10.1016/j.bmc.2015.05.059

  日期：2015.8

  13c, 13n, 13o, 13p, 13r, 13s, 13u and 24c obviously. By evaluation of inhibiting EGFR and HER2 kinases, seven compounds (13b, 13g, 13n, 13o, 13p, 13r and 13s) showed stronger EGFR potency with IC50 ⩽ 18 nM, which could also be understood by preliminary docking study of 13b with EGFR kinase. In view of the primary SAR, bisarylaniline derivatives (13o, 13p, 13r and 13s) showed obvious improvements on

  设计，合成了一系列新颖的4-芳基氨基-6 / 7-取代的5,6,7,8-四氢吡啶并[4,3- d ]嘧啶类化合物，它们作为潜在的抗增殖剂和EGFR激酶抑制剂具有生物活性被评估。THPPs中的N-丙烯酰胺片段和带有取代基的4-苯胺基团都起着关键作用，因为它们对四种癌细胞系（HT29，A549，H460和H1975）具有显着的抗增殖活性。吉非替尼抗性的H1975尤其抑制活性显示更有利的，这可从化合物可以观察到图13B，13C，13N，13O，13P，13R，13S，13u和24c显然。通过抑制EGFR和HER2激酶，七种化合物（评价13B，13克，13N，13O，13P，13R和13S）显示更强的EGFR效力与IC 50  ⩽18纳米，这也可以通过初步对接研究理解13b中与EGFR激酶。鉴于原发性SAR，双芳基苯胺衍生物（13o，13p，13r和13s）显示出对HER2抑制的明显改善，表明它们是潜在的EGFR
• Cyclohexane derivatives and their use as therapeutic agents
  申请人：——

  公开号：US20030236250A1

  公开（公告）日：2003-12-25

  The present invention relates compounds of formula (I), wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of formulae: (a), (b), (c), (d), and (e); and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 13 , R 14 , R 15 , R 16 , R 17 , R 21a and R 21b are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia. 1

  本发明涉及式(I)的化合物，其中环A是苯环或吡啶环；X代表从以下式组成的选择性连接物：(a)、(b)、(c)、(d)和(e)；以及R1、R2、R3、R4、R5、R6、R7、R13、R14、R15、R16、R17、R21a和R21b如本文所定义。这些化合物特别适用于治疗或预防抑郁症、焦虑、疼痛、炎症、偏头痛、呕吐或带状疱疹后神经痛。
• [EN] KINASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE KINASE ET LEURS UTILISATIONS
  申请人：DENALI THERAPEUTICS INC

  公开号：WO2018213632A1

  公开（公告）日：2018-11-22

  The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.

  本公开涉及化合物和组合物，中间体，它们的制备过程，以及它们作为激酶抑制剂的用途。